EU/3/18/1982

Table of contents

About

On 22 February 2018, orphan designation (EU/3/18/1982) was granted by the European Commission to ATXA Therapeutics Limited, Ireland, for N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide (also known as NTP42) for the treatment of pulmonary arterial hypertension.

Key facts

Active substance
N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide
Disease / condition
Treatment of pulmonary arterial hypertension
Date of decision
22/02/2018
Outcome
Positive
Orphan decision number
EU/3/18/1982

Sponsor's contact details

ATXA Therapeutics Limited
75 Avoca Park, Avoca Avenue
Blackrock
Co. Dublin
A94 N803 Ireland
Tel. +353 877765446
E-mail: therese.kinsella@atxatherapeutics.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating